First Albany Starts Altair Nanotechnologies (ALTI) at Neutral
- Wall Street rises as hawkish Fed boosts financial stocks
- Mylan (MYL) Plans to Launch Generic EpiPen; Will Cost 50% Less than Name Brand
- Dollar hits 3-week high vs yen as U.S. rate rise signals get louder
- Mylan's (MYL) Epipen4Schools Program is a Complicated Maze of Specialty Distribution Cos - Wells Fargo's Maris
- Pre-Open Stock Movers 08/29: (MCUR) (HLF) (MYL) Higher; (CZR) (ADMP) (KTOS) Lower (more...)
First Albany initiates coverage on Altair Nanotechnologies (Nasdaq: ALTI) with a Neutral rating.
You May Also Be Interested In
- UPDATE: Roth Capital Starts Neuralstem (CUR) at Buy
- Rodman & Renshaw Assumes Can-Fite BioPharma (CANF) at Buy
- Credit Suisse Starts First Hawaiian (FHB) at Outperform
Create E-mail Alert Related CategoriesNew Coverage
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!